Matches in Nanopublications for { <http://www.tkuhn.ch/bel2nanopub/RA9nrP7pWnY_HtpUa0fPfhqAuwY5AjmmmADeXuH3A4x8k#_5> ?p ?o ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- _5 value "To test whether mTOR would also phosphorylate Ser371 in vitro, Myc-S6K-WT derived from 293 cells pretreated with rapamycin was used as a direct substrate for HA-tagged mTOR immunopurified from 293 cells. The results show that Myc-mTOR-WT induces increased Ser371 phosphorylation in vitro as assessed by Western blot analysis with the Ser371 anti-phosphospecific antibody following electrophoresis on low acrylamide gels (Fig. 5A), consistent with in vivo findings (Fig. 2A). In contrast, HA-mTOR-KI had no effect. More importantly, in the presence of rapamycin and FKBP12, but not in the presence of either component alone, phosphorylation of Ser371 by mTOR is abolished (Fig. 5A), consistent with the in vivo finding (Fig. 4). In parallel, incubation of S6K1-E389D3E with HA-mTOR-WT also led to increased S6K1-E389D3E activation and Ser371 phosphorylation, in an FKBP-12/rapamycin-sensitive manner (Fig. 5B and data not shown). Furthermore, the extent of both responses was similar to those observed in vivo (compare Figs. 4B and 5B). Therefore, Ser371 phosphorylation appears to be directly regulated by mTOR in vitro and in vivo. (From full text) Incubation of either S6 kinase variant with wild type, but not kinase-inactive, mTOR led to increased Thr389 phosphorylation, with the extent of Thr389 phosphorylation much higher in S6K1-S371A than in wild type S6K1 (Fig. 6B). However, to achieve the same level of activity as S6K1-WT, S6K1-S371A apparently requires much higher levels of Thr389 phosphorylation (Fig. 6B), consistent with detailed titration studies (data not shown). Although unexpected, these findings are compatible with Ser371 phosphorylation regulating Thr389 phosphorylation and with its ability to directly affect S6K1 activity. (From full text)" provenance.
- _5 wasQuotedFrom 11914378 provenance.